ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Liquid Biopsy Market is expected to reach $10.4 Billion by 2027- An exclusive market research report by Lucintel

Lucintel’s latest market report analyzed that liquid biopsy provides attractive opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The liquid biopsy market is expected to reach $10.4 billion by 2027 with a CAGR of 17%. In this market, circulating tumor DNA (ctDNA) is the largest segment by circulating biomarker, whereas therapy selection is the largest segment by clinical application. The usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector provides strategic growth path in this market.

Download Brochure of this report by clicking on https://www.lucintel.com/liquid-biopsy-market.aspx

Based on circulating biomarker, the liquid biopsy market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers. Lucintel forecasts that the circulating tumor DNA (ctDNA) market accounted for the largest share of the market in 2020 and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.     

Browse in-depth TOC on “Liquid Biopsy Market”

129 – Tables

163 – Figures

264 – Pages

The liquid biopsy market is marked by the presence of several big and small players. Some of the prominent players offering liquid biopsy include Guardant, Bio-Rad Laboratories, Qaigen, MDxHealth, Myriad Genetics, Biocept, Roche, Illumina, and Thermofisher.  

Request Sample Report:

https://www.lucintel.com/liquid-biopsy-market.aspx

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: brandon.fitzgerald@lucintel.com
Tel. 972.636.5056
Cell: 303.775.0751

Related reports

Digital Fitness Market:

For more details click here https://www.lucintel.com/roofing-material-market.aspx

Medical Device Market:

For more details click here https://www.lucintel.com/medical-device-market.aspx

3D Printing Medical Device Market:

For more details click here https://www.lucintel.com/3d-printing-medical-device-market.aspx

Medical Lifting Sling Market:

For more details click here https://www.lucintel.com/medical-lifting-sling-market.aspx

Connected Health Device Market:

For more details click here https://www.lucintel.com/connected-health-device-market.aspx

Diagnostic Imaging Market:

For more details click here https://www.lucintel.com/diagnostic-imaging-market.aspx

Global Medical Battery Market:

For more details click here https://www.lucintel.com/medical-battery-market.aspx

Interventional Cardiology and Peripheral Vascular Device Market:

For more details click here https://www.lucintel.com/interventional-cardiology-peripheral-vascular-devi.aspx

 

Wheelchair Market Trends:

For more details click here https://www.lucintel.com/wheelchair-market.aspx

  

Coronary Stent Market:

For more details click here https://www.lucintel.com/stents-market.aspx

Contact Information:

Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: brandon.fitzgerald@lucintel.com
Tel. 972.636.5056
Cell: 303.775.0751

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.